NS-398

Name: NS-398
Brand: MedChemExpress
SKU: HY-13913
Rating: 5.0 (16 reviews)

Cat. No.: HY-13913 Purity: 99.71%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

NS-398 is a non-steroidal an-inflammatory agent with analgesic and antipyretic effects, and selectively inhibits prostaglandin G/H synthase 2/cyclooxygenase 2 (COX-2) activity, with an IC₅₀ of 3.8 μM, and has no effect on COX-1 at 100 μM.

For research use only. We do not sell to patients.

NS-398 Chemical Structure

CAS No. : 123653-11-2

Size	Stock	Quantity

Free Sample (0.1 - 0.5 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 16 publication(s) in Google Scholar

16 Publications Citing Use of MCE NS-398

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

COX-2

3.8 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	20 μM Compound: 1, NS-398	Inhibition of mPGES-1 in human A549 cell microsomes assessed as conversion of PGH2 into PGE2 at 0 degC after 5 mins by HPLC-UV analysis Inhibition of mPGES-1 in human A549 cell microsomes assessed as conversion of PGH2 into PGE2 at 0 degC after 5 mins by HPLC-UV analysis	[PMID: 22209272]
HaCaT	IC₅₀	10 nM Compound: NS-398	Inhibition of PGE2 production in human HaCaT cells after 24 hrs by RIA Inhibition of PGE2 production in human HaCaT cells after 24 hrs by RIA	[PMID: 15387642]
RAW264.7	IC₅₀	> 10 μM Compound: NS-398	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as nitrite accumulation after 20 hrs by fluorimetry Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as nitrite accumulation after 20 hrs by fluorimetry	[PMID: 11678654]
RAW264.7	IC₅₀	0.007 μM Compound: NS-398	Inhibition of mPGES-1 in mouse RAW264.7 cells assessed as reduction in LPS-induced PGE2 production after 24 hrs Inhibition of mPGES-1 in mouse RAW264.7 cells assessed as reduction in LPS-induced PGE2 production after 24 hrs	[PMID: 27720548]
RAW264.7	IC₅₀	0.007 μM Compound: NS-398	Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay	[PMID: 24656662]
RAW264.7	IC₅₀	0.00723 μM Compound: NS-398	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production after 24 hrs by enzyme immunoassay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production after 24 hrs by enzyme immunoassay	[PMID: 29107425]
RAW264.7	IC₅₀	0.05 μM Compound: NS-398	Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW264.7 cells by enzyme immunoassay	[PMID: 19233646]
RAW264.7	IC₅₀	0.1 μM Compound: NS-398	Inhibition of IFN-gamma/LPS-induced PGE2 production in mouse RAW264.7 cells after 17 to 20 hrs by EIA method Inhibition of IFN-gamma/LPS-induced PGE2 production in mouse RAW264.7 cells after 17 to 20 hrs by EIA method	[PMID: 25027933]
RAW264.7	IC₅₀	0.81 μM Compound: NS-398	Inhibition of COX2 in mouse RAW264.7 cells by enzyme immunoassay Inhibition of COX2 in mouse RAW264.7 cells by enzyme immunoassay	[PMID: 20056549]
RAW264.7	IC₅₀	2.1 μM Compound: NS-398	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as PGE2 accumulation after 20 hrs by RIA Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as PGE2 accumulation after 20 hrs by RIA	[PMID: 11678654]
RAW264.7	IC₅₀	4.8 μM Compound: NS-398	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production by EIA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production by EIA	[PMID: 20004572]
RAW264.7	IC₅₀	6.7 nM Compound: NS-398	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 31747281]
RAW264.7	IC₅₀	6.74 μM Compound: NS398	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA	[PMID: 28408221]
RAW264.7	IC₅₀	63.7 μM Compound: NS-398	Inhibition of COX1 in mouse RAW264.7 cells by enzyme immunoassay Inhibition of COX1 in mouse RAW264.7 cells by enzyme immunoassay	[PMID: 20056549]
RAW264.7	IC₅₀	7 nM Compound: NS-398	Suppression of PGE2 production in LPS-induced mouse RAW264.7 cells after 24 hrs by enzyme immunoassay Suppression of PGE2 production in LPS-induced mouse RAW264.7 cells after 24 hrs by enzyme immunoassay	[PMID: 26602278]
RAW264.7	IC₅₀	7.01 nM Compound: NS398	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production administered 1 hr prior to LPS-challenge measured after 24 hrs by EIA Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production administered 1 hr prior to LPS-challenge measured after 24 hrs by EIA	[PMID: 24360561]
RAW264.7	IC₅₀	7.23 nM Compound: NS-398	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production pretreated for 1 hr followed by LPS addition measured after 24 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production pretreated for 1 hr followed by LPS addition measured after 24 hrs	[PMID: 29102229]
SK-BR-3	IC₅₀	0.68 μM Compound: 1	Inhibition of aromatase in human SKBR3 cells by tritiated water release assay Inhibition of aromatase in human SKBR3 cells by tritiated water release assay	[PMID: 18271519]
SK-BR-3	IC₅₀	0.72 μM Compound: 2e	Cytotoxicity against human SK-BR-3 cells after 24 hrs by MTT assay relative to NS398 Cytotoxicity against human SK-BR-3 cells after 24 hrs by MTT assay relative to NS398	[PMID: 17095221]

In Vitro

NS-398 is a non-steroidal an-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity, with an IC₅₀ of 3.8 μM, and has no effect on COX-1 at 100 μM^[1]. NS-398 weakly inhibits PG endoperoxide synthase activity from sheep seminal vesicle microsomes (IC₅₀, 11 μM)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

NS-398 (0.5-10 mg/kg, p.o.) dose-dependently inhibits paw edema in rats, with an ED₃₀ of 1.14 mg/kg, shows therapeutic effects on adjuvant arthritis (ED₃₀, 4.69 mg/kg), exhibits dose-dependent analgesic activity (ED₅₀, 1.65 mg/kg), and has antipyretic effect (ED₅₀, 1.84 mg/kg) in rats. In mice, NS-398 suppresses writhing reactions induced by acetic acid with an ED₅₀ of 8.2 mg/kg^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

314.36

Formula

C₁₃H₁₈N₂O₅S

CAS No.

123653-11-2

Appearance

Solid

Color

Light yellow to yellow

SMILES

CS(=O)(NC1=CC=C([N+]([O-])=O)C=C1OC2CCCCC2)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL (106.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.1811 mL	15.9053 mL	31.8107 mL
5 mM	0.6362 mL	3.1811 mL	6.3621 mL
10 mM	0.3181 mL	1.5905 mL	3.1811 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (7.95 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (5.31 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.67 mg/mL (5.31 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.71%

Select Batch:

Data Sheet (280 KB) SDS (393 KB)

COA (250 KB) LCMS (98 KB)

Handling Instructions (2659 KB)

References

[1]. Futaki N, et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994 Jan;47(1):55-9. [Content Brief]

[2]. Futaki N, et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol. 1993 Jan;24(1):105-10. [Content Brief]

Animal Administration
^[2]

Mice^[2]
Briefly, male ddy mice weighing about 30 g are used. The writhing syndrome is induced by injecting 0.75% of acetic acid, intraperitoneally. Ten minutes later, the number of writhings are counted for the next 10 min. NS-398 is administered orally 30 min prior to the injection. The analgesic effect is expressed as % of inhibition, compared with the vehicle-treated control^[2].
Rats^[2]
Briefly, male Lewis rats weighing about 160 g are used. Arthritis is induced by injecting 0.1 mL of 0.7% Mycobacterium tubercu-losis-liquid paraffin into the left hind paw. On day 15, the rats are grouped according to the degree of secondary lesions in the right hind paw. NS-398 is administered orally once daily from days 15 to 18. Foot volume is measured on day 19. Relative edema volume (REV) is calculated for each animal^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Futaki N, et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994 Jan;47(1):55-9. [Content Brief]

[2]. Futaki N, et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol. 1993 Jan;24(1):105-10. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.1811 mL	15.9053 mL	31.8107 mL	79.5267 mL
	5 mM	0.6362 mL	3.1811 mL	6.3621 mL	15.9053 mL
	10 mM	0.3181 mL	1.5905 mL	3.1811 mL	7.9527 mL
	15 mM	0.2121 mL	1.0604 mL	2.1207 mL	5.3018 mL
	20 mM	0.1591 mL	0.7953 mL	1.5905 mL	3.9763 mL
	25 mM	0.1272 mL	0.6362 mL	1.2724 mL	3.1811 mL
	30 mM	0.1060 mL	0.5302 mL	1.0604 mL	2.6509 mL
	40 mM	0.0795 mL	0.3976 mL	0.7953 mL	1.9882 mL
	50 mM	0.0636 mL	0.3181 mL	0.6362 mL	1.5905 mL
	60 mM	0.0530 mL	0.2651 mL	0.5302 mL	1.3254 mL
	80 mM	0.0398 mL	0.1988 mL	0.3976 mL	0.9941 mL
	100 mM	0.0318 mL	0.1591 mL	0.3181 mL	0.7953 mL

NS-398 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

NS-398123653-11-2NS398NS 398COXCyclooxygenaseInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

NS-398

Customer Review

NS-398 Related Antibodies

16 Publications Citing Use of MCE NS-398

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

NS-398 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

NS-398 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report